1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Immunitas Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
HMPL-013 (1)
United States (1)